Mentoring patient-oriented researchers in pediatric diarrhea
指导以患者为中心的小儿腹泻研究人员
基本信息
- 批准号:10591728
- 负责人:
- 金额:$ 17.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-11 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAntibioticsAreaAwardBangladeshBig Data MethodsBioinformaticsBiological MarkersBiometryCause of DeathCessation of lifeChildChildhoodCholeraClinicalClinical ManagementCollaborationsCommunicable DiseasesComplementCountryDataData ScienceData SourcesDetectionDiagnosisDiagnosticDiagnostic testsDiarrheaEnrollmentEpidemiologyEtiologyFoundationsFrequenciesFundingFutureGoalsImmunologyIncomeIndividualInfectionInfrastructureKnowledgeMentorsMentorshipMethodsMicrobiologyMorbidity - disease ratePathogen detectionPhysiciansPlanet EarthPopulationProbabilityPrognosisPublic HealthQualitative MethodsResearchResearch DesignResearch PersonnelResource-limited settingRoleScientistSerologyStatistical MethodsTestingTimeTrainingTriageUnited States National Institutes of HealthUniversitiesUtahViralWorkantimicrobialbiomarker discoverybiomarker identificationcandidate identificationcandidate markercare seekingclinical careclinical decision supportclinical decision-makingclinical predictive modelclinical predictorscohortcostdiagnostic paneldiarrheal diseaseenteric infectionepidemiologic dataexperienceimprovedlow and middle-income countriesmetabolomicsmicrobialmolecular diagnosticspathogenpatient orientedpatient oriented researchpoint of carepredictive toolsprogramsremote sensingserosurveillancespatial integrationstatisticssupport toolstooltranscriptomics
项目摘要
Project Summary
Diarrheal illness is the second most common cause of non-neonatal death among young children worldwide,
and is a major cause of morbidity. Current etiologic diagnosis of diarrhea relies on microbial detection, and
decisions for antibiotics commonly empiric. However, the majority of cases of diarrhea do not benefit from
antibiotic use, and testing for all potential pathogens is neither financially nor logistically feasible. Thus,
methods to improve the clinical management of pediatric diarrheal illness, including strategies for antimicrobial
and diagnostic stewardship, are needed. Clinical prediction rules are potential tools to address this need, and
in this K24 application, our overall goal is to explore strategies to improve clinical decision-making for diarrhea
management, through use of spatial-temporal data and biomarkers. Dr. Leung, the PI, is a physician-scientist
with training in clinical infectious diseases, immunology, microbiology, and epidemiology, with a focus on
enteric infections, especially those that cause diarrheal illness in children in limited-resource settings. He has
mentored over 40 patient-oriented researchers (PORs) since the start of his independent research program in
2014; additionally, he has co-mentored numerous PORs in collaboration with scientists and clinicians working
in low- and middle-income countries. Leveraging infrastructure already in place from three ongoing NIH-funded
awards (R01AI130378, R01AI135114, R01AI135115), as well as Gates Foundation-funded studies, he
proposes to augment his current POR by addressing the following aims: 1) To examine the use of spatial-
temporal data for individual-level clinical prediction of pediatric diarrhea, where the use of A) serosurveillance,
B) molecular diagnostic, and C) earth observation-derived data will be explored, and 2) To identify clinical use-
cases, and potential candidates, of fecal biomarkers that complement clinical decision support tools for
management of pediatric diarrhea, using both qualitative methods to examine end-user perspectives and
identify use-cases, and metabolomics and transcriptomics methods to identify candidate biomarkers. To
accomplish these aims, he has established a co-mentoring team of experienced investigators with diverse
expertise in statistical methods, biomarker discovery, and mentoring of POR investigators. This award will
provide protected time for Dr. Leung to improve and increase his mentoring capacity of POR trainees, expand
his expertise and experience in bioinformatics, and generate data for future projects to improve the
management and knowledge of pediatric diarrheal infections.
项目摘要
腹泻病是全球幼儿中非肿瘤死亡的第二大最常见原因,
是发病率的主要原因。腹泻的当前病因学诊断依赖于微生物检测,并且
抗生素的决定通常是经验性的。但是,大多数腹泻病例并不能从中受益
抗生素的使用以及对所有潜在病原体的测试在财务上也不是可行的。因此,
改善小儿腹泻病的临床管理的方法,包括抗菌策略
需要诊断管理。临床预测规则是解决这一需求的潜在工具,并且
在此K24应用程序中,我们的总体目标是探索策略以改善腹泻的临床决策
通过使用时空数据和生物标志物,管理。 PI Leung博士是医师科学家
通过临床传染病,免疫学,微生物学和流行病学的培训,重点是
肠道感染,尤其是那些在限量资源环境中儿童引起腹泻病的感染。他有
自从他的独立研究计划开始以来,指导了40多名以患者为导向的研究人员
2014;此外,他还与科学家和临床医生合作,共同掌握了许多鲍尔
在低收入和中等收入国家。利用基础设施已经从三个正在进行的NIH资助的
奖项(R01AI130378,R01AI135114,R01AI135115),以及盖茨基金会资助的研究
提议通过解决以下目的来增加他当前的POR:1)检查空间的使用
小儿腹泻的个体临床预测的时间数据,其中使用a)血清监视,
b)分子诊断,c)将探索地球观测衍生的数据,以及2)确定临床使用 -
粪便生物标志物的病例和潜在候选者,这些疾病补充了临床决策支持工具
小儿腹泻的管理,使用两种定性方法来检查最终用户的观点和
识别用例,代谢组学和转录组学方法来识别候选生物标志物。到
完成这些目标,他建立了一个由经验丰富的调查员组成的团队
POR研究人员的统计方法,生物标志物发现和指导方面的专业知识。这个奖项将
为Leung博士提供受保护的时间,以提高和提高其POR学员的指导能力,扩大
他在生物信息学方面的专业知识和经验,并为未来项目生成数据以改善
小儿腹泻感染的管理和知识。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Ted Leung其他文献
Daniel Ted Leung的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Ted Leung', 18)}}的其他基金
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
- 批准号:
10522523 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
- 批准号:
10132972 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
- 批准号:
9912094 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
- 批准号:
10649542 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Development of clinical decision tools for management of diarrhea of children in high and low resource settings
开发资源丰富和匮乏环境下儿童腹泻管理的临床决策工具
- 批准号:
9912093 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Estimating Cholera Burden with Cross-sectional Immunologic Data
用横截面免疫学数据估计霍乱负担
- 批准号:
10388296 - 财政年份:2018
- 资助金额:
$ 17.19万 - 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
- 批准号:
10153667 - 财政年份:2017
- 资助金额:
$ 17.19万 - 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
- 批准号:
9926810 - 财政年份:2017
- 资助金额:
$ 17.19万 - 项目类别:
Mucosal associated invariant T (MAIT) cells in Vibrio cholerae infection and vaccination
霍乱弧菌感染和疫苗接种中的粘膜相关不变 T (MAIT) 细胞
- 批准号:
9398501 - 财政年份:2017
- 资助金额:
$ 17.19万 - 项目类别:
相似国自然基金
CTCF通过介导染色质高级结构调控非小细胞肺癌发生发展的机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
CTCF通过介导染色质高级结构调控非小细胞肺癌发生发展的机制研究
- 批准号:32100463
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
发展高级固体核磁方法探索功能材料的表界面化学
- 批准号:21922410
- 批准年份:2019
- 资助金额:120 万元
- 项目类别:优秀青年科学基金项目
TACSTD2在卵巢高级别浆液性癌发生发展中的作用及分子机制研究
- 批准号:81402157
- 批准年份:2014
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Establishment of a multi-center biobank of patient-specific induced pluripotent stem cells for pediatric sepsis research
建立用于儿童脓毒症研究的患者特异性诱导多能干细胞多中心生物库
- 批准号:
10649014 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
AIVIS: Next Generation Vigilant Information Seeking Artificial Intelligence-based Clinical Decision Support for Sepsis
AIVIS:下一代警惕信息寻求基于人工智能的脓毒症临床决策支持
- 批准号:
10699457 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms
开发一类针对碳青霉烯类耐药革兰氏阴性生物的新型肽抗生素
- 批准号:
10674131 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Koli: A non-surgical solution for gallstone disease
Koli:胆结石疾病的非手术解决方案
- 批准号:
10698949 - 财政年份:2023
- 资助金额:
$ 17.19万 - 项目类别:
Dissecting the molecular regulation of T cell localization and function within the Mycobacterium tuberculosis granuloma
剖析结核分枝杆菌肉芽肿内 T 细胞定位和功能的分子调控
- 批准号:
10351422 - 财政年份:2022
- 资助金额:
$ 17.19万 - 项目类别: